The Blueprint PD-L1 Immunohistochemistry (IHC) Assay Comparison Project also studied the performance of the four PD-L1 IHC assays (22C3, 28–8, SP142, and SP263) in NSCLC, and found -very similar to our results- an analytical comparability of 22C3, 28–8, and SP263 whereas the SP142 assay showed lowest levels of correlation [30]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.